A New FDA Approval Brings New Psychiatric Risks
The Carlat Psychiatry Podcast
00:00
Intro
This chapter covers the FDA's recent approval of Tonmeier, a sublingual cyclobenzaprine for fibromyalgia treatment, addressing its risks such as overdose and psychological effects in elderly patients. The discussion also includes a comparison of Tonmeier's efficacy to other medications, particularly pregabalin.
Transcript
Play full episode
